TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)
Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study
This study aims to evaluate the clinical effect, as reported by physicians, of an extensively hydrolyzed formula in young children aged 1~3 years with diagnosed with or highly suspected CMPA in a real-world clinical practice setting. The study will also evaluate the growth parameters, stool frequency and consistency, formula intake volume, gastrointestinal tolerance (including fussiness, flatulence, colic) and sleep disturbances, and any adverse events that may arise during the intervention period. This is a prospective, single-arm study including 50 young children at 1 hospital in China. Each participant will be followed for 90 days.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Cow's milk protein allergy (CMPA) is one of the most common food allergy in infancy and early childhood. The global overall prevalence ranges from 0.5% to 3% , and in some regions it can be as high as 4.9%. Currently, there are no nationwide epidemiological survey data on CMPA in China. However, local studies conducted in Chongqing, Hangzhou, and Zhuhai have reported a prevalence of 0.83% ~ 3.5% in infants aged 0 ~ 2 years. The pathogenesis of CMPA mainly includes IgE-mediated immediate-type hypersensitivity, non-IgE-mediated delayed-type hypersensitivity, and mixed-type reactions mediated by both mechanisms. Clinical manifestations may involve multiple organs and systems, including the skin, gastrointestinal tract, and respiratory tract. Dietary avoidance of cow's milk protein continues to be the main therapeutic approach, utilizing extensively hydrolyzed or amino acid-based formulas as determined by the degree of allergy.
Ages 1 ~ 3 years represent a critical window for the persistence of allergic symptoms and disease resolution in toddlers; approximately 85% ~ 90% of children with CMPA achieve clinical tolerance by around 3 years of age. Meanwhile, the age group of 1 ~ 3 years is also a critical period for dietary transition and the establishment of immune tolerance, during which children are particularly vulnerable to nutritional deficiencies. Therefore, special attention should be given to this age group, so that early diagnosis and appropriate interventions can be implemented to mitigate the impact of the disease on growth and development.
This is a prospective, longitudinal, single-arm study conducted at 1 hospital in China. The study will enroll young children aged 1~ 3 years with diagnosed with or highly suspected CMPA. Each participant will be followed for 90 days after the initiation of the investigational product. Parents or legal guardians will complete questionnaires regarding symptoms, gastrointestinal function, and product acceptability, while investigators will record clinical symptoms and anthropometric data using an electronic case report form (eCRF).
Collected data will include:
- Sociodemographic and baseline characteristics: sex, birth weight and length, gestational age, and family history of allergy.
- Anthropometric parameters: weight, length, and head circumference.
- Clinical assessments: Modified CoMiSS, SCORAD, and BSFS scores.
- Parent-reported outcomes: IGSQ-13, FAQL-PB, BISQ scores,and acceptability/satisfaction surveys.
- Safety outcomes: adverse events and concomitant medications.
A healthy reference group will include, which underwent only the modified CoMiSS assessment without exposure to the investigational product or involvement in efficacy/safety analyses, yielding normative reference benchmarks for the healthy population.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Qintong Duan
- Numero di telefono: +8613782669477
- Email: duanqintong@mengniu.cn
Luoghi di studio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200000
- Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
-
Contatto:
- Chenwai Xiao
- Numero di telefono: +8619121378960
- Email: xiaochenwai@scmc.com.cn
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
12 months≤ Age <36 months at enrollment.
-
Born at term at 37 ~ 42 weeks of gestation, with birth weight 2,500~4,000g.
-
Diagnosed with or highly suspected mild-to-moderate CMPA by a physician, meeting any of the following prior to enrollment:
- Positive serum cow's-milk-specific IgE (sIgE) >0.35 kUA/L (>0.7 kIU/L), combined with a detailed medical history; or a positive skin prick test (SPT);
- Positive result from a cow's milk protein elimination-challenge test;
- A documented medical history confirming CMPA within the 2 weeks prior to enrollment.
-
Hospitalization is not required and home intervention is considered appropriate by the investigator.
-
Written informed consent signed by a parent or legal guardian.
Exclusion Criteria:
- History of severe cows-milk-induced allergic reaction, such as anaphylactic shock.
- Underlying disease or history that may increase risk or affect gastrointestinal tolerance, growth, or development, including chronic systemic disease, congenital heart disease, chronic inflammatory bowel disease, malignant tumor, gastrointestinal malformation, or major congenital malformation.
- Laboratory abnormalities judged by the investigator to make participation inappropriate.
- Use of an extensively hydrolyzed formula or amino-acid formula within the preceding month.
- Participation in another interventional clinical trial within the preceding 90 days or currently.
- Inability to complete scheduled study visits
- Known intolerance to another ingredient in the study formula
- Any other condition judged inappropriate by the investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Diagnosed with or highly suspected CMPA: Extensively Hydrolyzed Formula intervention
|
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in investigator-reported allergy symptom scores
Lasso di tempo: Baseline, Day 30 ± 5, Day 90 ± 7
|
Change from baseline to D30 and D90 in investigator-assessed allergy symptoms in toddlers with diagnosed with or highly suspected cow's milk protein allergy, measured using four instruments. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in investigators measured or parent/caregiver-reported allergy symptom scores
Lasso di tempo: Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
Change from baseline to D30, D60 and D90 in investigators measured or parent/caregiver-reported symptoms, which will be analyzed according to improvement (reduction in score) or no improvement. |
Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
|
Change in z-scores for weight, length/height, and head circumference
Lasso di tempo: Baseline, Day 30 ± 5, Day 90 ± 7
|
Change in z-scores for weight, length/height, and head circumference calculated according to World Health Organization (WHO) growth standards. Differences between baseline, D30 and D90 will be summarized using descriptive statistics. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
|
Change in stool characteristics
Lasso di tempo: Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
Parent-reported stool characteristics (consistency and color), stool frequencies and stool types will be summarized for each visit. |
Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
|
Stool Samples Test Results
Lasso di tempo: Baseline, Day 30 ± 5, Day 90 ± 7
|
Abnormalities in routine stool examination and fecal occult blood test. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
|
Change in parental quality of life related to children allergy
Lasso di tempo: Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
Change in the Food Allergy Quality of Life-Parental Burden Questionnaire (FAQL-PB) score from baseline to Day 30, Day 60 and day 90. Improvement will be defined as a reduction in the total score. Descriptive statistics and frequencies of improvement will be presented. |
Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
|
Parental satisfaction with the investigational product
Lasso di tempo: Day 90 ± 7
|
Parent- or caregiver-reported satisfaction with the investigational product. |
Day 90 ± 7
|
|
Dietary intake
Lasso di tempo: Baseline, Day 30 ± 5, Day 90 ± 7
|
Assessment of dietary intake, including food categories and quantities (by weight), at baseline, on Day 30, and on Day 90 of the intervention. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
|
Adverse Events and Concomitant Medications
Lasso di tempo: From first intervention to Day 90 ± 7
|
Incidence, severity, and causal attribution to the study product of AEs and SAEs, together with concomitant medication use, throughout the study period. |
From first intervention to Day 90 ± 7
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ESEHF2-CMPA-202601
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .